Primary Objectives:~To compare the overall survival between subjects with advanced hepatocellular carcinoma treated with amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) or placebo radiofrequency electromagnetic fields (RF EMF).~To compare the patient-reported disease-related symptoms of subjects with advanced hepatocellular carcinoma treated with AM RF EMF or placebo RF EMF.~Secondary Objectives~To compare progression-free survival between subjects with advanced hepatocellular carcinoma treated with AM RF EMF or placebo RF EMF.~To compare safety and tolerability in this patient population between subjects with advanced hepatocellular carcinoma treated with AM RF EMF or placebo RF EMF.~To compare the effect on levels of alpha-fetoprotein between subjects with advanced hepatocellular carcinoma treated with AM RF EMF or placebo RF EMF.~To compare global treatment side effect bother between subjects with advanced hepatocellular carcinoma treated with AM RF EMF or placebo RF EMF.~To compare patient-rated symptomatic adverse events between subjects with advanced hepatocellular carcinoma treated with AM RF EMF or placebo RF EMF
The primary goal of this study is to gather efficacy data concerning overall survival with electromagnetic fields when compared to a placebo amplitude-modulated radiofrequency electromagnetic field device in subjects who have failed or are intolerant to at least two previous systemic therapies.